[[Bupropion/zonisamide]]

CATEGORIES: Anorectics, Antiobesity drugs, Combination drugs

Bupropion/zonisamide (planned trade name Empatic) is an experimental drug combination for the treatment of obesity.Empatic Shows Long-Term Weight Loss, Improved Quality Of Life Contrave(R) Reduces Rate Of Metabolic Syndrome By Half
It is being developed by Orexigen Therapeutics. It is currently at phase II testing.[tpl]cite journal|last=Ioannides-Demos|first=LL|coauthors=Piccenna, L; McNeil, JJ|title=Pharmacotherapies for obesity: past, current, and future therapies.|journal=Journal of Obesity|date=2011|volume=2011|pages=179674|doi=10.1155/2011/179674|pmid=21197148|url=http://downloads.hindawi.com/journals/jobe/2011/179674.pdf|format=PDF|pmc=3006492[/tpl][tpl]cite journal|last=Adan|first=RAH|title=Mechanisms underlying current and future anti-obesity drugs|journal=Trends in Neurosciences|date=February 2013|volume=36|issue=2|pages=133â€“140|doi=10.1016/j.tins.2012.12.001|pmid=23312373[/tpl] The combination consists of two prescription medications approved by the U.S. Food and Drug Administration (FDA) for other ailments.Orexigen says trial of 2nd obesity drug meets goal When mixed together and tested along with proper diet and moderate exercise, they produced a substantial weight loss effect higher than the group taking a placebo. 
Empatic was called Excalia before its name was changed.Empatic Obesity Drug Information and News

==References==


